Welcome to the latest edition of DNA Dispatch, the quarterly newsletter from OGT, your hybridization experts.
The new SureSeq™ Myeloid MRD Panel is OGT’s latest innovation in NGS solutions for hematological malignancies.
Unlock robust profiling of your samples with 13 key AML biomarkers, recommended by leading experts and ELN guidelines.
This highly-targeted panel allows you to focus on the biomarkers that are important to you, while keeping DNA input requirements low and workflows (both for sequencing and analysis) flexible.
OGT is excited to share with you we will be moving from plastic packaging to our new, sustainable packaging for CytoCell® products, an important step forward in our ongoing environmental efforts.
See how our CytoSure® arrays technology is utilized in the recent publication, "Genetic variants in DDX53 contribute to autism spectrum disorder associated with the Xp22.11 locus."*
From sample to tertiary insights, bring clarity to your workflow with our pioneering hybridization technology that fits seamlessly into your workflows.
Learn how to master CD138 cell enrichment for FISH, with tips on improving probe penetration, eliminating residual antibodies and more.
This article provides you with an understanding of this relationship between sequencing depth and VAF, which plays a significant role in accurately detecting genetic variants, especially in Measurable Residual Disease (MRD) detection.
Don’t forget…Our FAS team can be contacted online with free support advice
*Providing links to these publications is intended for educational purposes only and does not replace independent professional judgment. Statements of fact and opinions expressed are those of the publications’ authors and, unless expressly stated to the contrary, are not the opinion or position of the Oxford Gene Technology Group (OGT). OGT does not endorse or approve, and assumes no responsibility for, the content, accuracy or completeness of the information presented in these publications.